Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Key Takeaways

• HSR waiting period expired April 23, 2026.
• Merck offers $53 cash per Terns share.
• Closing requires tender of over 50% of Terns shares.
• Acquisition targets to broaden Merck’s pharmaceutical pipeline.
• Tender offer and related filings available on SEC website.

Pulse Analysis

The Hart‑Scott‑Rodino (HSR) waiting period is a mandatory antitrust review that can delay large mergers. Its expiration for Merck’s purchase of Terns Pharmaceuticals removes a regulatory bottleneck, allowing the cash tender offer to move toward completion. By meeting the HSR requirement, Merck demonstrates compliance with U.S. competition law, a critical step for any transaction exceeding $100 million in value. This clearance often signals to investors that the deal is on a firm trajectory, reducing uncertainty around the timeline and potential costs associated with prolonged legal reviews.

Merck’s $53‑per‑share cash offer reflects a strategic push to expand its biopharma pipeline. Terns brings a portfolio of novel therapeutics and advanced clinical programs that complement Merck’s existing oncology and vaccine assets. Integrating Terns could accelerate time‑to‑market for promising candidates, diversify revenue streams, and strengthen Merck’s position against rivals such as Pfizer and Johnson & Johnson. The acquisition also aligns with Merck’s broader objective to leverage cutting‑edge science for new treatments, supporting its long‑term growth narrative.

Investors should monitor the tender process closely, as the transaction hinges on securing more than half of Terns’ outstanding shares. The SEC filings, including the Schedule TO tender‑offer statement and Schedule 14D‑9 solicitation, provide detailed terms and conditions that may affect shareholder decisions. Should the required tender threshold be met, Merck will likely close the deal in the coming weeks, potentially triggering a revaluation of both companies’ stock. The move underscores a continued appetite for strategic acquisitions in the pharma industry, even as regulatory environments evolve.